Neurobiological Tech (NTII) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII)

NTII 0.0001000

0.0%

Mar 7 3:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Next 10PreviousNext

To: Miles Rhyne Hoffman, CFA who wrote ()	9/20/1996 12:31:00 PM
From: Howard Frederick	of 1494

A recent (PR Newswire) news release about dynorphin A Phase II clinicals indicated pretty good results. They plan on commencing to Phase III and are looking for a partner for that drug. I follow the company casually, don't own any shares, but may pick some up if I can get them for $4.50 or less. It is such a small company ($25-30MM market cap, depending on stock price) there is a lot of risk, but there is also a real reward if one of these drugs come through. I have seen posts in misc.invest.stocks where some knowledeable people look favorably on memantine in particular. I haven't been reading misc.invest.stocks for several months, so those opinions are dated.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Next 10PreviousNext